Lumenis Announces New Clinical Breakthroughs Using Its Patent-Protected MOSES(TM) Technology

Procedure time reduction in lithotripsy and benefits in BPH
treatments

Yokneam, Israel (ots/PRNewswire) - Lumenis Ltd.
(http://www.lumenis.com/), the world's largest energy-based medical
device company for surgical, aesthetic and ophthalmic applications,
announces the release of new clinical evidence and advantages in
lithotripsy and benign prostatic hyperplasia (BPH) treatments using
the MOSES(TM) Technology at the 34th annual European Association of
Urology Congress (EAU19), taking place in Barcelona, March 15-19,
2019.

For the last 30 years, holmium lasers and fibers have been
clinically proven as the gold-standard modality for the treatment of
urinary stones and BPH. Released by Lumenis two years ago, MOSES is a
revolutionary, patent-protected technology. MOSES utilizes a
proprietary combination of holmium lasers and fibers that optimize
holmium energy transmission using a unique pulse modulation.
Significant clinical evidence highlighting the benefits of MOSES in
lithotripsy has already been released, demonstrating that lithotripsy
procedures conducted with the MOSES technology result in 20% faster
procedures, 25% more efficient fragmentation, and 60% reduction in
stone retropulsion.

The advantages of MOSES for lithotripsy and BPH procedures are
being researched and demonstrated by leading academic institutions
worldwide. In BPH procedures, clinical evaluations are ongoing and
focused on studying advantages in enucleation of the prostate,
including smoother incision, better hemostasis and shorter procedure
time. In lithotripsy, the advantages of MOSES are studied across a
number of procedures and techniques including Mini PCNL, Ultra Mini
PCNL, Flexible Ureteroscopy and RIRS. These advantages will be
presented in a series of poster and video sessions by leading
worldwide key opinion leaders including:

- Dr. Khurshid Ghani of the University of Michigan, Ann Arbor (USA) -
Impact of variable pulse width and pulse modulation on dusting
effect for holmium laser lithotripsy: In vitro evaluation with
calcium oxalate monohydrate stones
- Dr. Oriol Angerri of Fundacio Puigvert, Barcelona (Spain) -
High-power holmium laser lithotripsy with MOSES Technology -
initial experience
- Prof. Thomas Knoll of Klinikverbund-Sudwest, Sindelfingen (Germany)
- Miniaturized percutaneous nephrolithotomy with MOSES laser
lithotripsy

MOSES will also take center stage during the EAU live surgery
plenary session:

- Dr. Karin Lehrich of Vivantes Auguste-Victioria Hospital, Berlin
(Germany) - MOSES Holmium Laser Enucleation of the Prostate (HoLEP)
for BPH
- Dr. Michael Lipkin of Duke University, Durham (USA) - MOSES Bladder
stone lithotripsy
- Dr. Oriol Angerri of Fundacio Puigvert, Barcelona (Spain) - MOSES
MiniPCNL
- Dr. Esteban Emiliani of Fundacio Puigvert, Barcelona (Spain) -
Flexible Ureteroscopy with the MOSES Technology

"Just two years since the launch of our patented MOSES Technology,
it brings us tremendous pride to see the urology community actively
researching and discovering its benefits for a wide range of urology
procedures," said Tzipi Ozer-Armon, CEO of Lumenis. "We are excited
to be at the forefront of urology care and part of this continuous
improvement in patient outcomes, and we are committed to continuing
the development of MOSES in a multitude of clinical applications"

During EAU19, attendees will be able to get a first-hand
experience of the technology in the 360 degree simulation lab at the
Lumenis booth I-26.

About Lumenis

www.lumenis.com

Lumenis is the world's largest energy-based medical device company
for surgical, aesthetic and ophthalmic applications in the area of
minimally invasive clinical solutions. Regarded as a world-renowned
expert in developing and commercializing innovative energy-based
technologies, including Laser, Intense Pulsed Light (IPL) and
Radio-Frequency (RF). For nearly 50 years, Lumenis' ground-breaking
products have redefined medical treatments and have set numerous
technological and clinical gold-standards. Lumenis has successfully
created solutions for previously untreatable conditions, as well as
designed advanced technologies that have revolutionized existing
treatment methods.

MEDIA CONTACT

Genevieve Britton

genevieve@pascalecommunications.com

Photo - https://mma.prnewswire.com/media/836129/Lumenis.jpg

Logo - https://mma.prnewswire.com/media/541530/Lumenis_Logo.jpg

ots Originaltext: Lumenis Ltd
Im Internet recherchierbar: http://www.presseportal.de

Contact:
+1.512.774.0735 (c)

Original-Content von: Lumenis Ltd, übermittelt durch news aktuell